Company Overview: VRX

Upcoming Projects (VRX)

Don’t see a project related to the company you care about? Create your own!

Executed Projects (VRX)

Don’t see a project related to the company you care about? Create your own!

Expired Projects (VRX)

How Much Will Brodamulab's (VRX) Troubled Past Impact its Potential on the Dermatology Market?
Ticker: VRX
Execute By: Sep 30, 2016
To see if we can get the specific DOJ requests to Pharma companies on drug pricing. These investigations have been confirmed in 10q filings.
Tickers: MRK, VRX, LLY
Execute By: Mar 04, 2016

Upcoming & Overdue Catalysts (VRX)

Don’t see a catalyst related to the company you care about? Create your own!

Occurred Catalysts (VRX)

FDA Approves Valeant's (VRX) PLENVU in colonoscopy bowel cleansing
Ticker: VRX
Occurred on: May 07, 2018
PDUFA Date of August 24th for Valeant's (VRX) Latanoprostene Bunod Ophthalmic Solution for Lowering Intraocular Pressure (IOP) in Patients with Open Angle Glaucoma or Ocular Hypertension
Tickers: VRX, COX.PA, Bausch + Lomb
Occurred on: Aug 07, 2017
Valeant (VRX) Files Marketing in Canada for Orexigen's (OREX) Obesity Pill Contrave
Tickers: VRX, OREX
Occurred on: Apr 25, 2017
Valeant (VRX) Announces Price of $3,500/month for Psoriasis Med Siliq
Ticker: VRX
Occurred on: Apr 21, 2017
Valeant (VRX) Announces Plans to Repurchase $1.1B of Oversubscribed 6.75% Senior Debt
Ticker: VRX
Occurred on: Mar 21, 2017
Valeant's (VRX) Bausch + Lomb Resubmits New Drug Application (NDA) for Latanoprostene Bunod Ophthalmic Solution for Lowering Intraocular Pressure in Patients with Open Angle Glaucoma or Ocular Hypertension
Tickers: VRX, Bausch + Lomb
Occurred on: Feb 27, 2017
Valeant's (VRX) Siliq Approved by FDA for Adults with Moderate-to-Severe Plaque Psoriasis
Tickers: VRX, AZN
Occurred on: Feb 16, 2017
Brodalumab in Moderate-to-Severe Plaque Psoriasis PDUFA set for February 16 2017
Ticker: VRX
Occurred on: Feb 16, 2017
Valeant (VRX) Announces Results from Second Phase 3 Trial Assessing IDP-118 Lotion for Plaque Psoriasis
Ticker: VRX
Occurred on: Jan 10, 2017
Top Line data of 2 Phase 3 trials for Bremelanotide in female sexual dysfunction (FSD)
Tickers: PTN, VRX
Occurred on: Nov 01, 2016
FDA Issues Guidance Clarifying the Requirements for Developers of Female Sexual Desire Drugs
Tickers: PTN, VRX
Occurred on: Oct 25, 2016
2nd Presidential Debate between Donald Trump and Hillary Clinton at Washington University in St. Louis, Missouri from 9 p.m. EDT to 10:30 p.m. EDT
Tickers: VRX, PFE, MYL, Turing Pharmaceuticals, GILD
Occurred on: Oct 09, 2016
FDA Approves ORKAMBI (lumacaftor/ivacaftor) for Use in Children with Cystic Fibrosis Ages 6 through 11 who have Two Copies of the F508del Mutation
Ticker: VRX
Occurred on: Sep 28, 2016
First Presidential debate between Donald Trump and Hillary Clinton at Hofstra University, New York, from 9 p.m. EDT to 10:30 p.m. EDT
Tickers: VRX, PFE, GILD, MYL
Occurred on: Sep 26, 2016
Zoetis' CFO leaves company to join Valeant
Tickers: ZTS, VRX
Occurred on: Aug 22, 2016
The concerns raised by the FDA in a CRL letter pertain to a Current Good Manufacturing Practice (CGMP) inspection at Bausch + Lomb's manufacturing facility in Tampa, Florida where some deficiencies were identified by the FDA
Ticker: VRX
Occurred on: Jul 22, 2016
Valeant To Participate In FDA Advisory Committee Meeting On July 19 to Review Valeant's BLA 761032 Brodalumab Subcutaneous Injection For Treatment of Adult Patients with Moderate to Severe Plaque Psoriasis
Ticker: VRX
Occurred on: Jul 19, 2016
PDUFA April 19 2016 of Oral RELISTOR for treatment of opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain
Tickers: PGNX, VRX
Occurred on: Jul 19, 2016
FDA Advisory Committee Recommends Approval Of Brodalumab For Treatment Of Moderate-To-Severe Plaque Psoriasis
Ticker: VRX
Occurred on: Jul 19, 2016
Valeant and Progenics Announce FDA Approves RELISTOR Tablets (450 mg once daily) for the Treatment of Opioid-Induced Constipation in Adults with Chronic Non-cancer Pain
Tickers: PGNX, VRX
Occurred on: Jul 19, 2016
Sequoia Fund's new leadership, second-biggest Valeant shareholder, elected to sell its position in Valeant Pharmaceuticals, exiting completely by mid-June
Ticker: VRX
Occurred on: Jul 12, 2016
Valeant Pharmaceuticals Announces Launch Of New PreserVision AREDS 2 Formula + Multivitamin
Ticker: VRX
Occurred on: Jun 16, 2016
The First Phase 3 trial for Plecanatide in IBS-C read out
Tickers: SGYP, PFE, AGN, VRX, IRWD
Occurred on: May 22, 2016
Valeant Pharmaceuticals Announces Expanded Discounts For Nitropress And Isuprel
Ticker: VRX
Occurred on: May 16, 2016
EyeGate Receives Additional Milestone Payment From Valeant Pharmaceuticals for EGP-437
Tickers: EYEG, VRX
Occurred on: Mar 02, 2016
Allergan (AGN) recieves FDA Acceptable for Filing Letter for Generic XIFAXAN® ANDA
Tickers: AGN, VRX
Occurred on: Feb 29, 2016
J. Michael Pearson to Return as CEO of Valeant Following Illness, Effective Immediately
Ticker: VRX
Occurred on: Feb 28, 2016
Valeant is withdrawing its prior financial guidance
Ticker: VRX
Occurred on: Feb 28, 2016
Valeant Announces FDA Acceptance of BLA Submission for Brodalumab in Moderate-to-Severe Plaque Psoriasis
Ticker: VRX
Occurred on: Jan 25, 2016
Pershing Square discloses that its stake in Valeant Pharmaceuticals is now 8.5% (29M shares), down from 9.9% (~34.1M shares).
Ticker: VRX
Occurred on: Dec 31, 2015
Valeant (VRX) Issues Statement in Response to Goldman Sachs Sell-off of Company Stock
Tickers: VRX, GS
Occurred on: Nov 06, 2015
Revance's (RVNC) RT002 Superior to Allergan's (AGN) BOTOX in Phase 2 Study Evaluating Treatment of Frown Lines
Tickers: RVNC, PFE, VRX, AGN
Occurred on: Oct 29, 2015
Valeant (VRX) Responds to Citron Research Report
Ticker: VRX
Occurred on: Oct 21, 2015
Valeant Pharmaceuticals (VRX) Down 20% after Citron Research Report Titled "Valeant, Could this be the Pharmaceutical Enron?"
Ticker: VRX
Occurred on: Oct 21, 2015
Allergan (AGN) Issues Statement Regarding Specialty Pharmacy Utilization and Resumes Trading
Tickers: AGN, PFE, VRX
Occurred on: Oct 21, 2015
Merck (MRK) Receives Inquiries Over Certain Aspects of Drug Pricing
Tickers: MRK, VRX, LLY, Turing
Occurred on: Oct 19, 2015
Allergan (AGN) Presents Paper Titled "Facial Treatment Preferences in Aesthetically-Oriented Men" at American Society of Dermatologic Surgery Meeting
Tickers: AGN, PFE, VRX
Occurred on: Oct 17, 2015
Allergan (AGN) Presents Data From Harmony Study on Combined Facial Aesthetic Treatment With Botox, Dermal Fillers, and Bimatoprost
Tickers: AGN, PFE, VRX
Occurred on: Oct 17, 2015
Valeant (VRX) Completes Tender Offer for Synergetics (SURG)
Tickers: VRX, SURG
Occurred on: Oct 15, 2015
Lilly (LLY) Receives Inquiries Over Certain Aspects of Drug Pricing (Date is an estimate for "September")
Tickers: LLY, VRX, MRK
Occurred on: Sep 15, 2015

Strategic Initiatives (VRX)

Subsidiary of Valeant (VRX) and EyeGate (EYEG) Announce Exclusive Global Licensing Agreement for EGP-437 and EyeGate II Delivery System in Ocular Surgery
Tickers: VRX, EYEG
Announcement Date: Feb 21, 2017
Valeant (VRX) Agrees to Sell Skincare Brands to L'Oreal (LRLCY) for $1.3 Billion
Tickers: VRX, LRLCY
Announcement Date: Jan 10, 2017
Valeant (VRX) Sells Dendreon Pharma to Sanpower Group for $819.9 MM Cash
Tickers: VRX, Dendreon Pharmaceuticals, Sanpower Group
Announcement Date: Jan 09, 2017
Orexigen Therapeutics Announces Commercialization and Distributorship Agreement with Valeant Canada for Contrave (naltrexone HCl / bupropion HCl extended release)
Tickers: OREX, VRX
Announcement Date: Aug 30, 2016

VRX Overview